Valo SPAC Presentation Deck
OPL-0401: Oral candidate with retinal exposure with the potential to
address complications of diabetes, including diabetic retinopathy (DR)
A ROCK1/2 inhibitor with oral dosing and
THERAPEUTIC preferential exposure in the retina could
HYPOTHESIS address currently underserved diabetic
retinopathy with an orally available therapeutic
OPL-0401 has potential for DR with expansion
across diabetic triopathy
OPL-0401 is designed to be orally available with
preferential retinal exposure, and to have better
comparable potency to known competitors
Differentiated PK/PD has been observed to reduce
systemic exposure, limiting typical ROCK AEs in
multiple studies
Potential opportunity to expand into diabetic
triopathy and other complications, to be evaluated
through pragmatic clinical trial
OPAL
VALIDATION
Pragmatic phase II trial designed to identify
responder cohorts, indications and intervention
approaches, and inform expansion across
diabetic triopathy²
Historical clinical proof of concept for ROCK inhibition in DR suggests potential
for OPL-0401
ROCK inhibition in combination with anti-VEGF has the potential to reduce central
macular thickness, including in VEGF-refractory DR¹
Severe diabetic macular edema despite
intravitreal (IVT) anti-VEGF treatment
Reduction in central macular thickness one
month after combined IVT ROCK inhibitor +
anti-VEGF
Effect of ROCK inhibition in combination with anti-VEGF was sustained over time (6 months)²
Valo expects to conduct a pragmatic phase II study for OPL-0401 with the goal of enhancing precision in DR and enabling
expansion into diabetic triopathy
OPL-0401 has been evaluated in multiple clinical studies to date, and has been observed to not lead to bradycardia or
tachyphylaxis at perceived therapeutic doses in studied patient populations
ROCK = Rho-associated kinase; anti-VEGF = anti-vascular endothelial growth factor; SoC = standard of care; DR = diabetic retinopathy; AE = adverse event
Valo [1] Nourinia, Ramin, et al. "Intravitreal Fasudil Combined with Bevacizumab for Treatment of Refractory Diabetic Macular Edema; A Pilot Study." Journal of Ophthalmic & Vision Research, Vol. 8 (4), 337-40. (Oct 2013).
[2] Reflects management's current expectations
2Q21
27View entire presentation